CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) – Equities research analysts at William Blair upped their FY2016 EPS estimates for CoLucid Pharmaceuticals in a research note issued on Thursday. William Blair analyst T. Lugo now anticipates that the brokerage will earn ($3.56) per share for the year, up from their prior forecast of ($3.81). William Blair also issued estimates for CoLucid Pharmaceuticals’ Q4 2016 earnings at ($0.85) EPS, FY2017 earnings at ($2.87) EPS, FY2018 earnings at ($2.91) EPS, FY2019 earnings at $2.08 EPS and FY2020 earnings at $5.00 EPS.

CLCD has been the subject of a number of other research reports. Piper Jaffray Cos. reiterated an “overweight” rating and set a $21.00 price objective on shares of CoLucid Pharmaceuticals in a report on Thursday, September 1st. Stifel Nicolaus lifted their price objective on shares of CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, September 19th. Zacks Investment Research lowered shares of CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 9th. Finally, Ladenburg Thalmann lifted their price objective on shares of CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 6th.

CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 35.20 on Monday. The company’s market cap is $677.46 million. The stock has a 50 day moving average of $33.91 and a 200 day moving average of $16.14. CoLucid Pharmaceuticals has a 52 week low of $4.30 and a 52 week high of $39.27.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN acquired a new position in CoLucid Pharmaceuticals during the third quarter worth approximately $201,000. Kornitzer Capital Management Inc. KS acquired a new position in CoLucid Pharmaceuticals during the third quarter worth approximately $381,000. Monashee Investment Management LLC acquired a new position in CoLucid Pharmaceuticals during the third quarter worth approximately $420,000. Northern Trust Corp acquired a new position in CoLucid Pharmaceuticals during the third quarter worth approximately $421,000. Finally, KCG Holdings Inc. acquired a new position in CoLucid Pharmaceuticals during the third quarter worth approximately $453,000. 31.44% of the stock is currently owned by institutional investors and hedge funds.

In other CoLucid Pharmaceuticals news, insider Linda C. Hogan sold 2,581 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $37.22, for a total transaction of $96,064.82. Following the transaction, the insider now owns 719 shares of the company’s stock, valued at approximately $26,761.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas P. Mathers sold 1,502 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $37.08, for a total transaction of $55,694.16. Following the transaction, the chief executive officer now directly owns 248,169 shares in the company, valued at approximately $9,202,106.52. The disclosure for this sale can be found here. Company insiders own 13.70% of the company’s stock.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Stock Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.